Mumbai, Nov. 6 --

Fredun Pharmaceuticals Limited (BSE - FREDUN | 539730), one of India's leading pharmaceutical formulation manufacturing companies, has announced its unaudited financial results for Q2 & H1 FY27. The Company offers a diversified portfolio spanning generics, cosmeceuticals, nutraceuticals, mobility solutions, and animal healthcare products.



Key Financial Highlights



Standalone key Financial Highlights - Q2 FY27



  • Total Income rose 84.21% YoY to Rs.267.64 Cr from Rs.145.29 Cr.
  • EBITDA rose 90.74% YoY to Rs.42.60 Cr from Rs.22.34 Cr.
  • EBITDA Margin improved 55 bps YoY to 15.92% from 15.37%.
  • Net Profit rose 93.44% YoY to Rs.18.83 Cr from Rs.9.73 Cr.
  • Net Profit Margin improved 34 bps YoY to 7.03% from 6.70%.


Standalone key Financial Highlights - H1 FY27



  • Total Income rose 87.02% YoY to Rs.495.88 Cr from Rs.265.15 Cr.
  • EBITDA rose 91.67% YoY to Rs.75.38 Cr from Rs.39.33 Cr.
  • EBITDA Margin improved 37 bps YoY to 15.20% from 14.83%.
  • Net Profit rose 93.92% YoY to Rs.31.99 Cr from Rs.16.50 Cr.
  • Net Profit Margin improved 23 bps YoY to 6.45% from 6.22%.


Recent Key Business Highlights



About Fredun Pharmaceuticals Limited



Fredun Pharmaceuticals Limited, healthcare and pharmaceuticals company offer a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary/herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products along with animal healthcare products. With such a diverse range of products, the Company's objective is to be a holistic healthcare provider. The Company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.



In the FY26, Fredun reported total revenues of Rs.639.12 Cr, with an EBITDA of Rs.94.79 Cr and a PAT of Rs.33.21 Cr.



Disclaimer



Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.





Published by HT Digital Content Services with permission from PNN.